Humira Revenue Up 9.6% In U.S., But Down Abroad Due To Biosimilars

Humira revenues fell 33.5% internationally in the third quarter of this year due to biosimilar competition, according to AbbVie, while revenues increased 9.6% in the United States, where there is no biosimilar competition until 2023. Humira tops the list of seven drugs with the biggest unsupported price increases, according to the Institute for Clinical and Economic Review . Humira is one of the high-profile cases of patent settlements that delay generic or biosimilar competition, though AbbVie says the settlements are...